The Rapid Evolution of Advanced Therapy Medicinal Products
The ATMP landscape continues to evolve rapidly, with cell and gene therapies moving closer to routine clinical use.
The growing number and diversity of advanced therapy products creates new challenges for developers and manufacturers, particularly in relation to process control, analytical methods, quality systems and regulatory compliance.
i-CELLBIO remains focused on supporting organisations operating within this evolving field through specialised ATMP, GMP and GLP consultancy.
EMA’s Committee for Advanced Therapies continues to publish quarterly updates on authorised ATMPs and developments within the field.
https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat?utm_source=chatgpt.com